Institution
Wayne State University
Education•Detroit, Michigan, United States•
About: Wayne State University is a education organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 42801 authors who have published 82738 publications receiving 3083713 citations. The organization is also known as: WSU & Wayne University.
Topics: Population, Cancer, Poison control, Pregnancy, Medicine
Papers published on a yearly basis
Papers
More filters
••
Stanford University1, Fred Hutchinson Cancer Research Center2, Wayne State University3, Ohio State University4, Stony Brook University5, University of California, Irvine6, Memorial Hospital of Rhode Island7, University of Wisconsin-Madison8, University of Texas Health Science Center at San Antonio9, University of California, Davis10, Memorial Hospital of South Bend11, University of California, Los Angeles12
TL;DR: Treatment with CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with prior hysterectomy, however, treatmentWith CEE increases the frequency of mammography screening requiring short interval follow-up, and initiation of CEE should be based on consideration of the individual woman's potential risks and benefits.
Abstract: ContextThe Women's Health Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopped early because of an increased stroke incidence and no reduction in risk of coronary heart disease. Preliminary results suggesting possible reduction in breast cancers warranted more detailed analysis.ObjectiveTo determine the effects of CEE on breast cancers and mammographic findings.Design, Setting, and ParticipantsFollowing breast cancer risk assessment, 10 739 postmenopausal women aged 50 to 79 years with prior hysterectomy were randomized to CEE or placebo at 40 US clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included.InterventionA dose of 0.625 mg/d of CEE or an identical-appearing placebo.Main Outcome MeasuresBreast cancer incidence, tumor characteristics, and mammogram findings.ResultsAfter a mean (SD) follow-up of 7.1 (1.6) years, the invasive breast cancer hazard ratio (HR) for women assigned to CEE vs placebo was 0.80 (95% confidence interval [CI], 0.62-1.04; P = .09) with annualized rates of 0.28% (104 cases in the CEE group) and 0.34% (133 cases in the placebo group). In exploratory analyses, ductal carcinomas (HR, 0.71; 95% CI, 0.52-0.99) were reduced in the CEE group vs placebo group; however, the test for interaction by tumor type was not significant (P = .054). At 1 year, 9.2% of women in the CEE group had mammograms with abnormalities requiring follow-up vs 5.5% in the placebo group (P<.001), a pattern that continued through the trial to reach a cumulative percentage of 36.2% vs 28.1%, respectively (P<.001); however, this difference was primarily in assessments requiring short interval follow-up.ConclusionsTreatment with CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with prior hysterectomy. However, treatment with CEE increases the frequency of mammography screening requiring short interval follow-up. Initiation of CEE should be based on consideration of the individual woman's potential risks and benefits.Trial Registrationclinicaltrials.gov Identifier: NCT00000611
558 citations
•
TL;DR: A statistically significant correlation between the presence of DAP-kinase gene promoter hypermethylation and lymph node involvement and advanced disease stage is detected and represents a promising serum marker for monitoring affected patients.
Abstract: Promoter hypermethylation is an important pathway for repression of gene transcription in cancer cells. We analyzed aberrant DNA methylation at four genes in primary tumors from 95 head and neck cancer patients and then used the presence of this methylation as a marker for cancer cell detection in serum DNA. These four genes were tested by methylation-specific PCR and included: p16 (CDKN2A), O6-methylguanine-DNA-methyltransferase, glutathione S-transferase P1, and death-associated protein kinase (DAP-kinase). Fifty-five % (52 of 95) of the primary tumors displayed promoter hypermethylation in at least one of the genes studied: 27% (26/95) at p16, 33% (31 of 95) at O6-methylguanine-DNA-methyltransferase; and 18% (17 of 92) at DAP-kinase. No promoter hypermethylation was observed at the glutathione S-transferase P1 gene promoter. We detected a statistically significant correlation between the presence of DAP-kinase gene promoter hypermethylation and lymph node involvement (P = 0.014) and advanced disease stage (P = 0.016). In 50 patients with paired serum available for epigenetic analysis, the same methylation pattern was detected in the corresponding serum DNA of 21 (42%) cases. Among the patients with methylated serum DNA, 5 developed distant metastasis compared with the occurrence of metastasis in only 1 patient negative for serum promoter hypermethylation (P = 0.056). Promoter hypermethylation of key genes in critical pathways is common in head and neck cancer and represents a promising serum marker for monitoring affected patients.
555 citations
••
TL;DR: Oral NaHCO(3) selectively increased the pH of tumors and reduced the formation of spontaneous metastases in mouse models of metastatic breast cancer, suggesting that inhibition of this tumor acidity will reduce the incidence of in vivo metastases.
Abstract: The external pH of solid tumors is acidic as a consequence of increased metabolism of glucose and poor perfusion. Acid pH has been shown to stimulate tumor cell invasion and metastasis in vitro and in cells before tail vein injection in vivo. The present study investigates whether inhibition of this tumor acidity will reduce the incidence of in vivo metastases. Here, we show that oral NaHCO3 selectively increased the pH of tumors and reduced the formation of spontaneous metastases in mouse models of metastatic breast cancer. This treatment regimen was shown to significantly increase the extracellular pH, but not the intracellular pH, of tumors by 31 P magnetic resonance spectroscopy and the export of acid from growing tumors by fluorescence microscopy of tumors grown in window chambers. NaHCO3 therapy also reduced the rate of lymph node involvement, yet did not affect the levels of circulating tumor cells, suggesting that reduced organ metastases were not due to increased intravasation. In contrast, NaHCO3 therapy significantly reduced the formation of hepatic metastases following intrasplenic injection, suggesting that it did inhibit extravasation and colonization. In tail vein injections of alternative cancer models, bicarbonate had mixed results, inhibiting the formation of metastases from PC3M prostate cancer cells, but not those of B16 melanoma. Although the mechanism of this therapy is not known with certainty, low pH was shown to increase the release of active cathepsin B, an important matrix remodeling protease. [Cancer Res 2009;69(6):2260–8]
554 citations
••
554 citations
••
University of Paris-Sud1, University of Louisville2, Pierre-and-Marie-Curie University3, University of Bonn4, University of Zurich5, University of Manchester6, University of Warwick7, Aix-Marseille University8, Karlsruhe Institute of Technology9, Wayne State University10, Niigata University11, Nara Women's University12, University of Cambridge13, Ludwig Maximilian University of Munich14, Chinese Academy of Sciences15, University of Bristol16, Jožef Stefan Institute17, Spanish National Research Council18, Imperial College London19, University of Milano-Bicocca20, CERN21, University of Victoria22, École Polytechnique Fédérale de Lausanne23, University of Cincinnati24, Novosibirsk State University25, Budker Institute of Nuclear Physics26, Fermilab27, Graduate University for Advanced Studies28, KEK29, University of Melbourne30, Indiana University31, University of Florida32, University of Ljubljana33
TL;DR: In this article, the authors report world averages of measurements of b-hadron, c-, c-, and tau-lepton properties obtained by the Heavy Flavor Averaging Group (HFAG) using results available through the end of 2011.
Abstract: This article reports world averages of measurements of b-hadron, c-hadron, and tau-lepton properties obtained by the Heavy Flavor Averaging Group (HFAG) using results available through the end of 2011. In some cases results available in the early part of 2012 are included. For the averaging, common input parameters used in the various analyses are adjusted (rescaled) to common values, and known correlations are taken into account. The averages include branching fractions, lifetimes, neutral meson mixing parameters, CP violation parameters, parameters of semileptonic decays and CKM matrix elements.
554 citations
Authors
Showing all 43073 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Eugene Braunwald | 230 | 1711 | 264576 |
Rakesh K. Jain | 200 | 1467 | 177727 |
Anil K. Jain | 183 | 1016 | 192151 |
Richard A. Gibbs | 172 | 889 | 249708 |
Bradley Cox | 169 | 2150 | 156200 |
Jun Wang | 166 | 1093 | 141621 |
David Altshuler | 162 | 345 | 201782 |
Elliott M. Antman | 161 | 716 | 179462 |
Jovan Milosevic | 152 | 1433 | 106802 |
Roberto Romero | 151 | 1516 | 108321 |
Kypros H. Nicolaides | 147 | 1302 | 87091 |
John F. Hartwig | 145 | 714 | 66472 |
Charles Maguire | 142 | 1197 | 95026 |
Mingshui Chen | 141 | 1543 | 125369 |